Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02320305 · ClinicalTrials.gov registry record · Early Phase 1
MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery
A Early Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 23
- Enrollment target
NCT02320305: Completed Early Phase 1 study, sponsored by Mayo Clinic.
NCT02320305 is a Early Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 23 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02320305, a Early Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from MART-1a peptide or antigen may help the body build an effective immune response to kill tumor cells. Giving TLR4 agonist GLA-SE with MART-1 antigen may help increase the immune response to MART-1a antigen.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL MART-1 Antigen
- DRUG TLR4 Agonist GLA-SE
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2015-01-27 |
| Est. Completion | 2019-04-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02320305
The ClinicalTrials.gov registry entry for NCT02320305 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02320305 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02320305 about?
NCT02320305 is a clinical study titled "MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery". This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or without toll-like receptor 4 (TLR4) agonist glucopyranosyl lipid A-stable oil-in-water emulsion (GLA-SE) in treating patients with stage II-IV melanoma that has been removed by surgery. Vac...
What is the current status of trial NCT02320305?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 23 participants. The study started on 2015-01-27. Estimated completion is 2019-04-11.
What interventions are being tested in trial NCT02320305?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), MART-1 Antigen (BIOLOGICAL), TLR4 Agonist GLA-SE (DRUG).
Who is sponsoring clinical trial NCT02320305?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.